StillCanna to Supply Hemp Biomass to Sequoya Cannabis


Today, Rich returns to one of his favorite cannabis companies. Though based in Canada, StillCanna Inc. (CSE:STIL) (OTCPK:SCNNF) is dedicated to large-scale CBD extraction in Europe.

Over the last few months, the company has been making incredible strides towards reaching its goal of being a global CBD supplier. In addition to key acquisitions that place it in a highly enviable position, StillCanna’s cultivation and extraction techniques are unrivaled in the CBD industry.

“StiillCanna is a company that’s very, very close to revenue. They are harvesting right now and they are extracting right now as well,” says Rich. “They have new extracting technology that nobody has.”

StillCanna to Supply Hemp Biomass to Sequoya

On Friday, StillCanna announced that it signed a definitive agreement to supply Sequoya Cannabis with $850,000 CAD worth of hemp biomass. The supply will consist of dried flower with a cannabinoid content of 5 percent or above and will be third-party tested to ensure that it’s of the highest quality.

StillCanna will derive the hemp biomass from its Polish farms. Of the company’s entire 2019 harvest, this supply will constitute about 3.5 percent, leaving plenty more hemp to be sold in future deals.

StillCanna CEO Jason Dussault, who Rich interviewed in July, had this to say about the Sequoya deal:

Enter Your E-mail Address To Subscribe

* indicates required

“This initial biomass agreement is in-line with the Company’s sales strategy. The more we speak with the principals of Sequoya the more we learn about the synergy of our Companies and the many ways we can work together beyond this initial agreement. From cooperative marketing, research, and product development we feel there are multiple benefits for our firms to work together in the European market.”

Rich notes how beneficial it can be for a Canadian company to focus on the European market.

“The Euro is so much higher than the Canadian dollar,” he says. “So when you’re generating sales in Europe, and then you’re converting those sales into Canadian dollars, you’re making a huge spread right off the bat. So from that perspective, I see huge opportunity here.”

More StillCanna News Worth Celebrating

In the last month alone, StillCanna has passed some huge milestones. On July 31, it accepted delivery of its first custom-built harvesters designed specifically for hemp. Within a week, these harvesters were put to work collecting the cannabis flower with minimal disruption to the cannabinoid crystals. This process ensures that the harvested product retains maximum CBD content.

On August 12, the company released key information regarding its state-of-the-art extraction facility in Poland. Termed Nexus, the facility is designed for a production capacity that exceeds 1,000 kgs of isolate a month and is on track to be operational by Q4 2019.

On top of its impressive Polish holdings, StillCanna also has a JV facility in Romania with Dragonfly Biosciences that is in the final stages of being licensed.

Even more than its farms and facilities, the company has reason to be proud of its cultivation and extraction methods. Its ethanol extraction method can create large quantities of high-quality CBD at a remarkably low cost. On top of that, its proprietary hemp strain has a gestation period of just 45 days. This means that, starting next year, StillCanna can plant and harvest two crops every season.

“I cannot wait to see the revenue growth for this company,” Rich says. “I believe it’s going to be exponential and they are going to be a huge success.”

StillCanna Presents a Unique Buying Opportunity

At its IPO, the company’s stock price was just $0.025. Since then it has shot up to a high of $1.64 and now sits at $0.59. This presents investors with a rare chance to buy into an early-stage company in an incredibly lucrative market.

“To be able to get into a CBD company when it’s about to start selling—and it’s under $0.60 in Canada—this is an amazing opportunity,” says Rich.

According to the Brightfield Group, the CBD market in Europe was worth $318 million in 2018, and by 2023 will grow by 400 percent. CBD is just starting to explode in Europe, and StillCanna is incredibly well-positioned to meet this fast-growing demand.

What do you think? Will CBD be the next big play for cannabis investors? Let us know your opinions in the comments below.

Featured image: Canva

Please See Disclaimer

If You Liked This Article Click To Share


1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, StillCanna Inc. Bitrics Markets Group Inc. and/or Iman Consulting Group has or expects to receive $800 Canadian dollars from Market Jar Media Inc. for the creation and distribution of the video.

3) Statements and opinions expressed are the opinions of the author and not Bitrics Markets Group Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Bitrics Markets Group Inc. for this Article. Bitrics Markets Group Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Bitrics Markets Group Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Bitrics Markets Group Inc. relies upon the authors to accurately provide this information and Bitrics Markets Group Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Bitrics Markets Group Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Bitrics Markets Group Inc. does not render general or specific investment advice and the information on should not be considered a recommendation to buy or sell any security. Bitrics Markets Group Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on

5) Bitrics Markets Group Inc. and its owners, members, officers, directors, partners and consultants may own shares of the profiled companies, which it may sell at any time, including as soon as it deposits such shares into its trading accounts, during our campaign of the profiled companies stock, after our campaign or at any other time. We also may buy and sell securities in the profiled companies which may cause (a) decline in the price of the profiled companies stock due to our selling activities, (b) increased volatility due to our buying and selling of the profiled companies stock and (c) permit us to make substantial profits while we are profiling each of these companies, yet may result in a diminished value to the stock for investors. for any company mentioned in the Article.